Aducanumab: a new phase in therapeutic development for Alzheimer’s disease?

Alzheimer's disease

(2021) Philip Scheltens et al.   LANCET

Donanemab in Early Alzheimer’s Disease

(2021) Mark A. Mintun et al.   NEW ENGLAND JOURNAL OF MEDICINE

Evaluation of Aducanumab for Alzheimer Disease

(2021) G. Caleb Alexander et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer’s disease with lecanemab, an anti-Aβ protofibril antibody

(2021) Chad J. Swanson et al.   Alzheimers Research & Therapy

Landmark Alzheimer’s drug approval confounds research community

(2021) Asher Mullard   NATURE

A trial of gantenerumab or solanezumab in dominantly inherited Alzheimer’s disease

(2021) Stephen Salloway et al.   NATURE MEDICINE

FDA's green light, science's red light

(2021) Joel S. Perlmutter   SCIENCE

The “rights” of precision drug development for Alzheimer’s disease

(2019) Jeffrey Cummings et al.   Alzheimers Research & Therapy

Gantenerumab reduces amyloid-β plaques in patients with prodromal to moderate Alzheimer’s disease: a PET substudy interim analysis

(2019) Gregory Klein et al.   Alzheimers Research & Therapy

The Cellular Phase of Alzheimer’s Disease

(2016) Bart De Strooper et al.   CELL

The amyloid cascade hypothesis for Alzheimer's disease: an appraisal for the development of therapeutics

(2011) Eric Karran et al.   NATURE REVIEWS DRUG DISCOVERY

The development of antiretroviral therapy and its impact on the HIV-1/AIDS pandemic

(2009) Samuel Broder   ANTIVIRAL RESEARCH